Related references
Note: Only part of the references are listed.Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
Beatriz Grinsztejn et al.
LANCET (2007)
Development of integrase inhibitors for treatment of AIDS: An overview
Sonal Dubey et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2007)
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals
Martin Markowitz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients
Edwin DeJesus et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Integrase inhibitors to treat HIV/AIDS
Y Pommier et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase
K Zhu et al.
JOURNAL OF VIROLOGY (2004)
Repair of gaps in retroviral DNA integration intermediates
KE Yoder et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
